Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RuRe1
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
RuRe1 is a heteronuclear ruthenium(II)-rhenium(I) complex, specifically [Ru(bpy)2(tpphz)Re(CO)3Cl](PF6)2, where bpy is 2,2'-bipyridine and tpphz is a tetrapyrido[3,2-a:2',3'-c:3″,2″-h:2″',3″'-j]phenazine bridging ligand. It is designed as a photodynamic therapy (PDT) agent for cancer treatment. RuRe1 exhibits high phototoxicity against various cancer cell lines upon irradiation with blue light (450 nm). Its mechanism of action involves inducing tumor cell apoptosis via the mitochondrial pathway and inhibiting metastasis and angiogenesis by downregulating the expression of matrix metalloproteinases 2 and 9 (MMP-2, MMP-9) and vascular endothelial growth factor receptor 2 (VEGFR2).
- Other names
- [Ru(bpy)2(tpphz)Re(CO)3Cl](PF6)2Ru(II)-Re(I) heteronuclear metal complex
Beyond the preview
Go deeper on RuRe1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RuRe1.